Switch theme
Sign up to access all valuation multiples
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
2002
209
LTM Revenue $59.7M
LTM EBITDA -$7.6M
$164M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Exagen has a last 12-month revenue (LTM) of $59.7M and a last 12-month EBITDA of -$7.6M.
In the most recent fiscal year, Exagen achieved revenue of $55.6M and an EBITDA of -$11.1M.
Exagen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Exagen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $59.7M | XXX | $55.6M | XXX | XXX | XXX |
| Gross Profit | $35.9M | XXX | $33.1M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$7.6M | XXX | -$11.1M | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -20% | XXX | XXX | XXX |
| EBIT | -$11.9M | XXX | -$13.6M | XXX | XXX | XXX |
| EBIT Margin | -20% | XXX | -25% | XXX | XXX | XXX |
| Net Profit | -$13.6M | XXX | -$15.1M | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Exagen's stock price is $7.
Exagen has current market cap of $152M, and EV of $164M.
See Exagen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $164M | $152M | XXX | XXX | XXX | XXX | $-0.72 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Exagen has market cap of $152M and EV of $164M.
Exagen's trades at 3.0x EV/Revenue multiple, and -14.8x EV/EBITDA.
Equity research analysts estimate Exagen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Exagen has a P/E ratio of -11.2x.
See valuation multiples for Exagen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $152M | XXX | $152M | XXX | XXX | XXX |
| EV (current) | $164M | XXX | $164M | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | -21.8x | XXX | -14.8x | XXX | XXX | XXX |
| EV/EBIT | -13.8x | XXX | -12.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.2x | XXX | -10.1x | XXX | XXX | XXX |
| EV/FCF | -11.5x | XXX | -11.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialExagen's last 12 month revenue growth is 16%
Exagen's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Exagen's rule of 40 is -20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Exagen's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Exagen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -20% | XXX | XXX | XXX |
| EBITDA Growth | -92% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -20% | XXX | -4% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 84% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Exagen acquired XXX companies to date.
Last acquisition by Exagen was XXXXXXXX, XXXXX XXXXX XXXXXX . Exagen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Exagen founded? | Exagen was founded in 2002. |
| Where is Exagen headquartered? | Exagen is headquartered in United States of America. |
| How many employees does Exagen have? | As of today, Exagen has 209 employees. |
| Who is the CEO of Exagen? | Exagen's CEO is Mr. John Aballi. |
| Is Exagen publicy listed? | Yes, Exagen is a public company listed on NAS. |
| What is the stock symbol of Exagen? | Exagen trades under XGN ticker. |
| When did Exagen go public? | Exagen went public in 2019. |
| Who are competitors of Exagen? | Similar companies to Exagen include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Exagen? | Exagen's current market cap is $152M |
| What is the current revenue of Exagen? | Exagen's last 12 months revenue is $59.7M. |
| What is the current revenue growth of Exagen? | Exagen revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Exagen? | Current revenue multiple of Exagen is 2.8x. |
| Is Exagen profitable? | Yes, Exagen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Exagen? | Exagen's last 12 months EBITDA is -$7.6M. |
| What is Exagen's EBITDA margin? | Exagen's last 12 months EBITDA margin is -13%. |
| What is the current EV/EBITDA multiple of Exagen? | Current EBITDA multiple of Exagen is -21.8x. |
| What is the current FCF of Exagen? | Exagen's last 12 months FCF is -$14.3M. |
| What is Exagen's FCF margin? | Exagen's last 12 months FCF margin is -24%. |
| What is the current EV/FCF multiple of Exagen? | Current FCF multiple of Exagen is -11.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
